Mazdutide vs Zepbound: Glucagon vs GIP Dual Agonists

Mazdutide and Zepbound are both dual-agonist weight-loss drugs that pair GLP-1 with a second hormone, but they choose different partners, and that’s the heart of this comparison: mazdutide adds glucagon, while Zepbound adds GIP. Zepbound produces more weight loss and is approved in the US, while mazdutide is approved only in China. Here’s how these two dual-hormone approaches compare and what the choice of second hormone means.

Two Dual Agonists, Different Second Hormones

Both drugs go beyond single-hormone GLP-1 therapy by adding a second target, but they diverge on which one. Zepbound (tirzepatide) combines GLP-1 with GIP, a hormone that enhances weight loss and improves how the body handles nutrients. Mazdutide combines GLP-1 with glucagon, a hormone that increases calorie burning and reduces liver fat. So while both are “dual agonists,” they’re mechanistically distinct, and that difference shapes their effects.

Head to Head

Weight Loss: Zepbound Leads Slightly

On weight loss, Zepbound has a modest edge. Tirzepatide produced up to about 21% in its pivotal SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022. Mazdutide produced roughly 15% to 20% depending on dose in its Chinese trials, with the highest dose approaching 20%. So they’re in a similar range, with Zepbound somewhat ahead, though direct comparisons across different trial populations are imprecise.

What the Glucagon Difference Adds

Mazdutide’s glucagon component gives it a distinctive angle: beyond weight loss, glucagon’s direct effect on the liver may make mazdutide particularly useful for people with fatty liver issues, and it increases energy expenditure. Zepbound’s GIP component, meanwhile, has its own metabolic benefits. Consider a hypothetical patient with obesity and fatty liver: mazdutide’s glucagon-driven liver effects might be appealing in theory, though Zepbound also improves liver fat and is the option actually available in the US.

Availability: The Decisive Difference

This is where the comparison is settled for US patients. Zepbound is FDA approved and widely available. Mazdutide, despite being a genuine milestone (the first glucagon-containing weight-loss drug approved anywhere), is approved only in China, not by the FDA, so it isn’t available in the US at all. For anyone outside China, Zepbound is the accessible dual agonist, while mazdutide remains unavailable.

What This Means for You Right Now

Mazdutide is not available in the US, and TrimRx does not offer it. Zepbound (tirzepatide) is among the brand options TrimRx offers, alongside compounded tirzepatide and compounded semaglutide and other brand GLP-1 medications. If you want a powerful dual-agonist option you can actually start, tirzepatide-based treatment is available now, while mazdutide remains a China-only drug.

Frequently Asked Questions

Is mazdutide or Zepbound more effective?

Zepbound (tirzepatide) has a slight edge, producing up to about 21% weight loss versus roughly 15% to 20% for mazdutide. They’re in a similar range, but cross-trial comparisons aren’t exact, and Zepbound is the more established option.

What’s the difference between glucagon and GIP in these drugs?

Both are the “second hormone” added to GLP-1. Mazdutide adds glucagon (which increases calorie burning and reduces liver fat), while Zepbound adds GIP (which enhances weight loss and nutrient handling). This makes them mechanistically different despite both being dual agonists.

Can I get mazdutide in the US?

No. Mazdutide is approved only in China, not by the FDA, so it’s unavailable in the US. Zepbound is FDA approved and available, and TrimRx offers tirzepatide-based options.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Mazdutide is not approved in the US; details may change. Consult a healthcare provider before starting any medication. Individual results may vary.